18F-FMAU PET/CT and MRI for the Detection of Brain Tumors in Patients With Brain Cancer or Brain Metastases
NCT04752267 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 10
Last updated 2024-05-24
Summary
This early phase I trial tests the use of a radioactive tracer (a drug that is visible during an imaging test) known as 18F-FMAU, for imaging with positron emission tomography/computed tomography (PET/CT) in patients with brain cancer or cancer that has spread to the brain (brain metastases). A PET/CT scan is an imaging test that uses a small amount of radioactive tracer (given through the vein) to take detailed pictures of areas inside the body where the tracer is taken up. 18F-FMAU may also help find the cancer and how far the disease has spread. Magnetic resonance imaging (MRI) is a type of imaging test used to diagnose brain tumors. 18F-FMAU PET/CT in addition to MRI may make the finding and diagnosing of brain tumor easier.
Conditions
- Anatomic Stage IV Breast Cancer AJCC v8
- Clinical Stage IV Cutaneous Melanoma AJCC v8
- Glioma
- Malignant Brain Neoplasm
- Metastatic Breast Carcinoma
- Metastatic Colon Carcinoma
- Metastatic Kidney Carcinoma
- Metastatic Lung Carcinoma
- Metastatic Malignant Neoplasm in the Brain
- Metastatic Melanoma
- Pathologic Stage IV Cutaneous Melanoma AJCC v8
- Prognostic Stage IV Breast Cancer AJCC v8
- Stage IV Colon Cancer AJCC v8
- Stage IV Lung Cancer AJCC v8
- Stage IV Renal Cell Cancer AJCC v8
- Stage IVA Colon Cancer AJCC v8
- Stage IVA Lung Cancer AJCC v8
- Stage IVB Colon Cancer AJCC v8
- Stage IVB Lung Cancer AJCC v8
- Stage IVC Colon Cancer AJCC v8
Interventions
- PROCEDURE
-
Computed Tomography
Undergo PET/CT
- DRUG
-
18F-FMAU
Given IV
- PROCEDURE
-
Multiparametric Magnetic Resonance Imaging
Undergo mpMRI
- PROCEDURE
-
Positron Emission Tomography
Undergo PET/CT
Sponsors & Collaborators
-
National Cancer Institute (NCI)
collaborator NIH -
University of Southern California
lead OTHER
Principal Investigators
-
Hossein Jadvar, MD · University of Southern California
Study Design
- Allocation
- NA
- Purpose
- DIAGNOSTIC
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2021-02-15
- Primary Completion
- 2023-09-18
- Completion
- 2023-09-18
- FDA Drug
- Yes
Countries
- United States
Study Locations
More Related Trials
-
[18F] FACBC and [18F] FLT PET Imaging in Central Nervous System Tumors
NCT00832598 ·Status: COMPLETED ·Phase: NA
-
Study to Establish the Diagnostic Performance of 18F Fluciclovine PET in Detecting Recurrent Brain Metastases
NCT04410133 ·Status: COMPLETED ·Phase: PHASE3
-
18F-FLUC PET/MR in Patients With Brain Mets
NCT06159335 ·Status: RECRUITING ·Phase: PHASE3
-
Evaluation of the Efficacy and Safety of [18F]-ML-10, as a PET Imaging Radiotracer, in Early Detection of Response of Brain Metastases of Solid Tumors to Radiation Therapy.
NCT00805636 ·Status: UNKNOWN ·Phase: PHASE2
-
Evaluating the Usefulness of 18F-AlF-FAPI PET/ CT in Orbital Neoplasms
NCT06791226 ·Status: RECRUITING ·Phase: NA
-
18F-FAPI-04 PET/CT and PET/MR in Patients With Various Types of Malignant Tumors
NCT06557590 ·Status: RECRUITING
-
PET and/or MRI Scans in Assessing Tumor Response in Patients Receiving Antiangiogenesis Therapy
NCT00019565 ·Status: COMPLETED ·Phase: PHASE1
-
PET Imaging of Intracranial Cancers With 18F-FSPG
NCT02370563 ·Status: TERMINATED ·Phase: PHASE1
-
18F-FLT PET/CT in Measuring Cell Proliferation in Patients With Brain Tumors
NCT02167204 ·Status: COMPLETED ·Phase: NA
-
18F-AlF-FAPi-04 PET/CT Imaging in Patients With Solid Tumor
NCT06126705 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
An Investigational Scan (18F-DOPA PET/CT) for Improving the Clinical Management of Brain Tumors
NCT06667726 ·Status: RECRUITING ·Phase: PHASE2
-
18F-Fluorocholine (18F-FCho) to Distinguish Necrosis From Recurrence in Brain Metastases
NCT02037945 ·Status: COMPLETED ·Phase: NA
-
18F-FSPG PET/CT Imaging in Patients With Cancers
NCT03144622 ·Status: UNKNOWN
-
Study to Establish Image Interpretation Criteria for 18F Fluciclovine PET in Detecting Recurrent Brain Metastases (PURSUE)
NCT04410367 ·Status: COMPLETED ·Phase: PHASE2
-
Comparison of 6-fluoro-[18F]-L-dihydroxyphenylalanine (18F-DOPA) Positron Emission Tomography (PET) and Multiparametric Resonance Magnetic Imagery (RMI) in Initial Exploration of Glial Tumors
NCT03525080 ·Status: COMPLETED ·Phase: NA
-
18F-FMAU PET/CT in Diagnosing and Characterizing Prostate Cancer
NCT02809690 ·Status: TERMINATED ·Phase: PHASE1
-
Role of [18F]-FDG Brain PET in Newly Diagnosed Primary Cerebral Lymphoma, in Immunocompetent Patient Older Than 60 Years
NCT03582254 ·Status: UNKNOWN ·Phase: NA
-
Feasibility of 18F-Fluciclovine PET/CT to Identify Brain Metastasis
NCT06055790 ·Status: RECRUITING ·Phase: PHASE2
-
3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer
NCT00935090 ·Status: RECRUITING
-
PET Imaging of High-grade Glioma Using 18F-fluoromethylcholine: a Tool for the Early Detection of Tumour Recurrence After Combined Radiochemotherapy?
NCT00628940 ·Status: COMPLETED ·Phase: PHASE1
-
Fludeoxyglucose (FDG) F 18 PET Scan, CT Scan, and Ferumoxtran-10 MRI Scan Before Chemotherapy and Radiation Therapy in Finding Lymph Node Metastasis in Patients With Locally Advanced Cervical Cancer or High-Risk Endometrial Cancer
NCT00416455 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
18F-DOPA-PET/MRI Scan in Imaging Elderly Patients With Newly Diagnosed Grade IV Malignant Glioma or Glioblastoma During Planning for a Short Course of Proton Beam Radiation Therapy
NCT03778294 ·Status: COMPLETED ·Phase: PHASE2
-
[18F]Fluciclovine and [18F]FLT PET/CT Assessment of Primary High-Grade Brain Tumors
NCT03276676 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy
NCT01806675 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
[18F]Dabrafenib Molecular Imaging in Melanoma Brain Metastasis
NCT02700763 ·Status: TERMINATED ·Phase: NA